Загрузка...
Tumor refractoriness to anti-VEGF therapy
Vascular endothelial growth factor (VEGF) has been identified as the most potent cytokine involved in tumor angiogenesis and metastasis formation. Clinical results of anti-angiogenic therapies targeting VEGF and its receptors are very modest, resulting in a moderate improvement of overall survival....
Сохранить в:
| Опубликовано в: : | Oncotarget |
|---|---|
| Главный автор: | |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Impact Journals LLC
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5216828/ https://ncbi.nlm.nih.gov/pubmed/27081695 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8694 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|